Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg.
It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose. The product will be marketed under store brand labels and is comparable to the brand Zyrtec®.
Shares of Marksans Pharma Limited was last trading in BSE at Rs. 61.65 as compared to the previous close of Rs. 61.20. The total number of shares traded during the day was 311130 in over 2417 trades.
About Cetirizine Hydrochloride
Cetirizine is a second generation antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Cetirizine is used to treat cold or allergy symptoms such as sneezing, itching, watery eyes, or runny nose.
Cetirizine is also used to treat an allergic reaction, itching and swelling caused by chronic urticaria (hives) and minimizes or eliminates the symptoms of perennial allergic rhinitis, seasonal allergic rhinitis, chronic idiopathic urticaria, allergic asthma, physical urticaria, and atopic dermatitis.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)